News Releases:

2011

miRagen Therapeutics Publishes Data Demonstrating that Therapeutic Dosing of miR-15 Family Inhibitor Protects Against Ischemic Injury to the Heart

Results suggest therapeutic targeting could provide protective effects Study published in today’s online edition of Circulation Research   Boulder, CO, November 3, 2011 – MiRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA... View »

Servier and Miragen Sign $352 Million Partnership Agreement for the Research, Development and Commercialization of MicroRNA-targeting Drugs for Cardiovascular Disease

Miragen retains all U.S. and Japanese commercialization rights; Servier gains rights to all other global markets Servier to fund multi-year research and development plan on various targets and all preclinical and clinical development costs through Phase II for the... View »

Therapeutic Dosing of Synthetic AntimiR Further Demonstrates the Potential of microRNA-208 Inhibition in Treatment of Chronic Heart Failure

Research by miRagen Therapeutics published in Circulation Boulder, CO, September 6, 2011 – miRagen Therapeutics, Inc., a preclinical-stage biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced that new... View »

RxGen and miRagen Announce Award of NIH-NHLBI SBIR Grant to Fund Advanced Preclinical Studies Evaluating the Role of microRNAs in Cardiac Disease

HAMDEN, Conn., and BOULDER, Colo., August 25, 2011 – RxGen, a specialty preclinical contract research organization, and miRagen Therapeutics, Inc., a preclinical-stage biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle... View »

miRagen Therapeutics and Collaborators Identify Critical Role of microRNA-15 in Cardiomyogenesis

Results suggest therapeutic targeting could provide regenerative effects Data published in Circulation Research Boulder, CO, July 26, 2011 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and... View »

miRagen Therapeutics and Collaborators Identify Key Role for miR-133a as a Modulator of Skeletal Muscle Disorder

Data published in The Journal of Clinical Investigation Boulder, CO, July 1, 2011 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that... View »

miRagen Receives Notice of Allowance for Intellectual Property for MicroRNAs that Modulate Smooth Muscle Proliferation and Differentiation

Long-term partnership between miRagen and UT Southwestern Medical Center yields its first broad microRNA patent BOULDER, CO, June 21, 2011 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for... View »

miRagen Therapeutics Receives Orphan Drug Designation for MGN-4893 for the Treatment of Polycythemia Vera

Drug candidate targets microRNA-451, a recently discovered key regulator of blood cell development BOULDER, Colo., February 17, 2011 – miRagen Therapeutics, Inc., a privately-held biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular... View »

miRagen to Present New Data at First Keystone MicroRNAs and Human Disease Conference

miRagen Lead Scientists serve as Scientific Organizers of Conference miRagen presentations to focus on microRNA biology in the progression of cardiovascular and muscle disease and the potential for therapeutic intervention BOULDER, CO, Feb. 11, 2011 – miRagen Therapeutics, Inc.,... View »

miRagen Therapeutics Named University of Colorado Technology Transfer Office Bioscience Company of the Year

BOULDER, Colo., January 18, 2011 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that it is the recipient of the University of... View »